GLPG.AS
Galapagos NV News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 1,
"returned": 1,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "1a61773a-0bd2-46e5-8b5b-cd90715130af",
"title": "Galapagos NV (NASDAQ:GLPG) Q1 2024 Earnings Call Transcript",
"description": "Sofie Van Gijsel: Welcome all to the audio webcast of Galapagos' Q1 2024 Results. I'm Sofie Van Gijsel, Investor Relations representing the reporting team at Galapagos.",
"keywords": "",
"snippet": "Galapagos NV (NASDAQ:GLPG) Q1 2024 Earnings Call Transcript May 4, 2024\n\nGalapagos NV isn’t one of the 30 most popular stocks among hedge funds at the end of ...",
"url": "https://www.insidermonkey.com/blog/galapagos-nv-nasdaqglpg-q1-2024-earnings-call-transcript-1297770/",
"image_url": "https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2023/10/14192815/GLPG-insidermonkey-1697326092942.jpg",
"language": "en",
"published_at": "2024-05-06T14:47:45.000000Z",
"source": "insidermonkey.com",
"relevance_score": null,
"entities": [
{
"symbol": "GLPG.AS",
"name": "Galapagos NV",
"exchange": null,
"exchange_long": null,
"country": "nl",
"type": "equity",
"industry": "Healthcare",
"match_score": 110.69918,
"sentiment_score": 0.235929,
"highlights": [
{
"highlight": "<em>Galapagos</em> <em>NV</em> (NASDAQ:GLPG) Q1 2024 Earnings Call Transcript May 4, 2024\n\n<em>Galapagos</em> <em>NV</em> isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).\n\nSofie Van Gijsel: Welcome all to the audio webcast of <em>Galapagos</em>’ Q1 2024 Results.",
"sentiment": 0.7239,
"highlighted_in": "main_text"
},
{
"highlight": "I’m Sofie Van Gijsel, Investor Relations representing the reporting team at <em>Galapagos</em>. This recorded webcast is accessible via the <em>Galapagos</em> website homepage and will be available for download and replay later on today. I would like to remind everyone that we will be making forward-looking statements during today’s webcast.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "Because these forward-looking statements involve risks and uncertainties, <em>Galapagos</em>’ actual results may differ materially from the results expressed or implied in these statements.\n\nToday’s speakers will be Paul Stoffels, CEO; and Thad Huston, CFO and COO. Paul will reflect on the first quarter of 2024 and present the corporate update.",
"sentiment": -0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "I would like to take a minute to start with our foundation, our vision and mission, which we presented shortly after I joined <em>Galapagos</em> in 2022 and which informs all we do. We aim to transform patient outcomes through life-changing science and innovation for more years of life and quality of life.",
"sentiment": 0.7269,
"highlighted_in": "main_text"
},
{
"highlight": "And with the recent transfer of Jyseleca business to Alfasigma, we have transformed <em>Galapagos</em> into a pure-play biotech with a revitalized pipeline and put in place the tools we need to meet our future growth ambitions.",
"sentiment": 0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "Q&A Session\n\nFollow <em>Galapagos</em> <em>Nv</em> (NASDAQ:GLPG) Follow <em>Galapagos</em> <em>Nv</em> (NASDAQ:GLPG) or Subscribe with Google We may use your email to send marketing emails about our services. Click here to read our privacy policy.\n\nOperator: [Operator Instructions]. And now we’re going to take our first question. It comes from the line of Xian Deng from UBS.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Galapagos</em> <em>NV</em> (NASDAQ:GLPG) Q1 2024 Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "GLPG.AS",
"total_documents": 1,
"sentiment_avg": 0.2359289973974228
}
]
}
Other details
Exchange
- Euronext Amsterdam
- equity
- Healthcare
- nl